Molecular profiling of DLBCL patients treated in the PETAL trial

Using whole-exome sequencing and shallow whole genome sequencing for simultaneous screening of mutations, copy number alterations, and translocations, 5 biology-based risk profiles could be reproduced in an independent cohort of DLBCL patients, from the PETAL trial.

Type: Other
Archiver: European Genome-Phenome Archive (EGA)

1 Dataset 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001008386	Shallow whole genome sequencing and targeted sequencing of DLBCL patients treated in the PETAL trial	Illumina HiSeq 4000 Illumina NovaSeq 6000	216

Publications	Citations
Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma. Mendeville MS, Janssen J, Los-de Vries GT, van Dijk E, Richter J, Nijland M, Roemer MGM, Stathi P, Hijmering NJ, Bladergroen R, Pelaz DA, Diepstra A, Eertink CJ, Burggraaff CN, Kim Y, Lugtenburg PJ, van den Berg A, Tzankov A, Dirnhofer S, Dührsen U, Hüttmann A, Klapper W, Zijlstra JM, Ylstra B, de Jong D. Nat Commun 16: 2025 109	1

Publications

Citations

Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma.
Mendeville MS, Janssen J, Los-de Vries GT, van Dijk E, Richter J, Nijland M, Roemer MGM, Stathi P, Hijmering NJ, Bladergroen R, Pelaz DA, Diepstra A, Eertink CJ, Burggraaff CN, Kim Y, Lugtenburg PJ, van den Berg A, Tzankov A, Dirnhofer S, Dührsen U, Hüttmann A, Klapper W, Zijlstra JM, Ylstra B, de Jong D. Nat Commun 16: 2025 109